RFSH (Follitropin)

Evidence in perspective

The named U.S. product label is the appropriate source for its approved use, contraindications and handling. GONAL-f subcutaneous follitropin alfa: terminal half-life was about 24 hours in healthy down-regulated women, 32 hours in IVF/embryo-transfer patients, and 32–41 hours in healthy men depending on repeated versus single dosing. Absorption affects the observed elimination rate; one generic value would obscure these differences. A label extraction is not an independent appraisal of every supporting trial or approval of other products with the same ingredient.

Who was studied

The population specified by this product label; other indications and jurisdictions remain outside this check.

What the sources found

Selected infertility indications in women and men, with specialist assessment and monitoring.

Regulatory scope

U.S. label record for BLA020378. This does not confer authorization on other products using the ingredient name.

What remains unknown

Named-product label sections were expanded for pharmacokinetics, contraindications and selected handling or interaction details on September 7, 2026. This is not a complete trial-program appraisal or clinician sign-off. Other formulations, patient-specific decisions and other jurisdictions require separate assessment.

How it works

GONAL-f follitropin alfa multidose powder vials

Consult the product label for pharmacology. A mechanism does not extend its approved indications.

Approved product exists

Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.

Understanding the evidence

Reported adverse effects

• Ovarian hyperstimulation, vascular complications and serious hypersensitivity are important warnings.

Named U.S. presentation only; selected label sections.

Source · Warnings and precautions / boxed warning